Abstract
ObjectivesTo assess the contribution of CYP2C9/VKORC1 genotypes and variation in other genes involved in warfarin biotransformation and coagulation pathways to warfarin‐related outcomes in children. Furthermore, to validate the performance of a previously published pediatric pharmacogenetics‐dosing model when predicting the required dose in an independent cohort of children.MethodsClinical and genetic data was collected from 93 patients ≤18 years of age who received warfarin therapy. Genotyping was performed using a custom 96 SNP genotyping assay.ResultsTogether, VKORC1–1639G/A and CYP2C9 *2/*3 accounted for 21.1% of dose variability. There was a strong correlation (R2=0.64; P<0.001) between actual and predicted warfarin dose using a pediatric pharmacogenetics‐dosing model. VKORC1 genotype also had a significant impact on time to therapeutic INR (P=0.047), time to INR>;4 (P=0.028), and risk of over‐anticoagulation (INR>;4) during the initiation of therapy (odds ratio, 3.3; P=0.014). An additional variant in CYP2C9 (rs7089580) was significantly associated with warfarin dose in a multivariate model.ConclusionsThis study confirms the importance of VKORC1/CYP2C9 genotype for warfarin outcomes in children and validates a pediatric‐specific genotype‐based dosing algorithm. Research funding provided by CIHR‐DSEN and CFI.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
